Mateos, M. Et Al. 2023. Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.5 , 1172-1177.

Mateos, M., Rigaudeau, S., Basu, S., Spicka, I., Schots, R., Wrobel, T., ... Cook, G.(2023). Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.5, 1172-1177.

Mateos, Maria-Victoria Et Al. "Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.5, 1172-1177, 2023

Mateos, Maria-Victoria Et Al. "Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.5, pp.1172-1177, 2023

Mateos, M. Et Al. (2023) . "Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.29, no.5, pp.1172-1177.

@article{article, author={Maria-Victoria Mateos Et Al. }, title={Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2023, pages={1172-1177} }